ArticleScientific reports2025
Formulation and characterization of BBR loaded niosomes using saponin as a nonionic biosurfactant investigating synergistic effects to enhance antibacterial activity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Enhanced anti Pseudomonas aeruginosa efficacy of niosomal-encapsulated Frondoside A from sea cucumber: a novel biotechnological approach.BMC biotechnology · 2026Article
- Chitosan-Coated Niosomal Nanocarriers for the Co-Delivery of Glibenclamide and Curcumin in Diabetes Mellitus.Polymers · 2026Article
- Preparation and Characterization of Niosomes Containing Cationic Antimicrobial Peptides WSKK11 and WSRR11.ACS omega · 2026Article
- Deciphering the efficacy of staphyloxanthin-encapsulated niosomal nanovesicles to attenuate biofilm formation, quorum sensing, and meropenem persistence in Acinetobacter baumannii.BMC microbiology · 2025Article
- Antifungal efficacy of cinnamaldehyde and nano-cinnamaldehyde particles against candidiasis: an in-vitro study.BMC oral health · 2025Article
- Staphyloxanthin loaded niosomal nanocarrier augments its anthelmintic activity against Trichinella spiralis infection in mice.Scientific reports · 2025Article
- A Comprehensive Review of Niosomes: Composition, Structure, Formation, Characterization, and Applications in Bioactive Molecule Delivery Systems.Molecules (Basel, Switzerland) · 2025Review
- Thermo-Responsive Niosomal In Situ Gels for Topical Delivery of Prednisolone.AAPS PharmSciTech · 2025Article
- Optimization andAnti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to enhance the antibacterial efficacy of BBR, a natural alkaloid with limited bioavailability and solubility, by encapsulating it in niosomes using saponin as a biosurfactant. Niosomes, non-ionic surfactant-based vesicles, improve drug stability and targeted delivery. The niosomes were synthesized using a ball milling-assisted method to optimize particle size and encapsulation efficiency. The formulation was characterized for particle size, zeta potential, encapsulation efficiency, and release kinetics. Niosomes with saponin had a particle size of 185 nm, a negative zeta potential, and the slowest release rate, following the Higuchi model. BBR-loaded niosomes achieved impressive entrapment efficiency (E.E%) of up to 93.7. The addition of saponin was expected to boost the antibacterial effects through synergistic mechanisms. The antibacterial efficacy of the formulation was assessed against Staphylococcus aureus and Escherichia coli. The resulting niosomal formulation exhibited significantly improved antibacterial activity compared to free BBR. The minimum bactericidal concentration (MIC) of the niosomes containing saponin (NSa2) and BBR against S. aureus and E. coli was found to be 0.08 ± 0.0 mg/ml. In contrast, the MBC of BBR alone against S. aureus was 0.24 ± 0.02 mg/ml, while for E. coli, it was 0.25 ± 0.02 mg/ml. These findings suggest that this niosomal formulation could be a promising approach for delivering BBR with improved therapeutic efficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.